Glilar M2 Tablet ER is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 500mg extended-release. It is indicated for the management of type 2 diabetes mellitus, particularly in patients whose blood glucose levels are inadequately controlled by diet, exercise, and monotherapy. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to release insulin, thereby enhancing insulin secretion. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, resulting in better glycemic control. The extended-release formulation of Metformin in Glilar M2 facilitates a gradual release of the drug, improving gastrointestinal tolerability and enhancing patient compliance through once-daily dosing. This combination therapy offers complementary mechanisms of action, addressing multiple pathophysiological defects in type 2 diabetes. Glilar M2 should be used as part of a comprehensive diabetes management plan, including diet and exercise. It is contraindicated in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia. Common adverse effects may include gastrointestinal disturbances and hypoglycemia. Regular monitoring of blood glucose levels and renal function is recommended during therapy. Dose adjustments should be individualized based on therapeutic response and tolerability.